147 related articles for article (PubMed ID: 38064957)
1. A model of subcutaneous pramlintide pharmacokinetics and its effect on gastric emptying: Proof-of-concept based on populational data.
Furió-Novejarque C; Sala-Mira I; Díez JL; Bondia J
Comput Methods Programs Biomed; 2024 Feb; 244():107968. PubMed ID: 38064957
[TBL] [Abstract][Full Text] [Related]
2. A model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes.
Ramkissoon CM; Aufderheide B; Bequette BW; Palerm CC
J Diabetes Sci Technol; 2014 May; 8(3):529-42. PubMed ID: 24876617
[TBL] [Abstract][Full Text] [Related]
3. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM.
Kong MF; Stubbs TA; King P; Macdonald IA; Lambourne JE; Blackshaw PE; Perkins AC; Tattersall RB
Diabetologia; 1998 May; 41(5):577-83. PubMed ID: 9628276
[TBL] [Abstract][Full Text] [Related]
4. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM.
Kong MF; King P; Macdonald IA; Stubbs TA; Perkins AC; Blackshaw PE; Moyses C; Tattersall RB
Diabetologia; 1997 Jan; 40(1):82-8. PubMed ID: 9028722
[TBL] [Abstract][Full Text] [Related]
5. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
Singh-Franco D; Robles G; Gazze D
Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
[TBL] [Abstract][Full Text] [Related]
6. Ultra-Fast Insulin-Pramlintide Co-Formulation for Improved Glucose Management in Diabetic Rats.
Maikawa CL; Chen PC; Vuong ET; Nguyen LT; Mann JL; d'Aquino AI; Lal RA; Maahs DM; Buckingham BA; Appel EA
Adv Sci (Weinh); 2021 Nov; 8(21):e2101575. PubMed ID: 34499434
[TBL] [Abstract][Full Text] [Related]
7. Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes.
Fang J; Landersdorfer CB; Cirincione B; Jusko WJ
AAPS J; 2013 Jan; 15(1):15-29. PubMed ID: 23054970
[TBL] [Abstract][Full Text] [Related]
8. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus.
Vella A; Lee JS; Camilleri M; Szarka LA; Burton DD; Zinsmeister AR; Rizza RA; Klein PD
Neurogastroenterol Motil; 2002 Apr; 14(2):123-31. PubMed ID: 11975712
[TBL] [Abstract][Full Text] [Related]
9. In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes.
Micheletto F; Dalla Man C; Kolterman O; Chiquette E; Herrmann K; Schirra J; Kovatchev B; Cobelli C
Diabetes Technol Ther; 2013 Oct; 15(10):802-9. PubMed ID: 23865841
[TBL] [Abstract][Full Text] [Related]
10. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
Rodriguez LM; Mason KJ; Haymond MW; Heptulla RA
Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
[TBL] [Abstract][Full Text] [Related]
11. Pramlintide and the treatment of diabetes: a review of the data since its introduction.
Younk LM; Mikeladze M; Davis SN
Expert Opin Pharmacother; 2011 Jun; 12(9):1439-51. PubMed ID: 21564002
[TBL] [Abstract][Full Text] [Related]
12. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
Ryan GJ; Jobe LJ; Martin R
Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
[TBL] [Abstract][Full Text] [Related]
13. Pramlintide acetate.
McQueen J
Am J Health Syst Pharm; 2005 Nov; 62(22):2363-72. PubMed ID: 16278328
[TBL] [Abstract][Full Text] [Related]
14. Effects of delayed gastric emptying on postprandial glucose kinetics, insulin sensitivity, and β-cell function.
Hinshaw L; Schiavon M; Mallad A; Man CD; Basu R; Bharucha AE; Cobelli C; Carter RE; Basu A; Kudva YC
Am J Physiol Endocrinol Metab; 2014 Sep; 307(6):E494-502. PubMed ID: 25074985
[TBL] [Abstract][Full Text] [Related]
15. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.
Kolterman OG; Schwartz S; Corder C; Levy B; Klaff L; Peterson J; Gottlieb A
Diabetologia; 1996 Apr; 39(4):492-9. PubMed ID: 8778001
[TBL] [Abstract][Full Text] [Related]
16. Pramlintide for the treatment of diabetes mellitus.
Kleppinger EL; Vivian EM
Ann Pharmacother; 2003; 37(7-8):1082-9. PubMed ID: 12841822
[TBL] [Abstract][Full Text] [Related]
17. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes.
Weinzimer SA; Sherr JL; Cengiz E; Kim G; Ruiz JL; Carria L; Voskanyan G; Roy A; Tamborlane WV
Diabetes Care; 2012 Oct; 35(10):1994-9. PubMed ID: 22815298
[TBL] [Abstract][Full Text] [Related]
18. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition.
Samsom M; Szarka LA; Camilleri M; Vella A; Zinsmeister AR; Rizza RA
Am J Physiol Gastrointest Liver Physiol; 2000 Jun; 278(6):G946-51. PubMed ID: 10859225
[TBL] [Abstract][Full Text] [Related]
19. Primer on pramlintide, an amylin analog.
Traina AN; Kane MP
Diabetes Educ; 2011; 37(3):426-31. PubMed ID: 21471470
[TBL] [Abstract][Full Text] [Related]
20. ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes.
Andersen G; Meiffren G; Famulla S; Heise T; Ranson A; Seroussi C; Eloy R; Gaudier M; Charvet R; Chan YP; Soula O; DeVries JH
Diabetes Obes Metab; 2021 Apr; 23(4):961-970. PubMed ID: 33336850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
